GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome. / Hellström, P M; Näslund, E; Edholm, T; Schmidt, P T; Kristensen, J; Theodorsson, E; Holst, Jens Juul; Efendic, S.

In: Neurogastroenterology and Motility Online, Vol. 20, No. 6, 06.2008, p. 649-59.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Hellström, PM, Näslund, E, Edholm, T, Schmidt, PT, Kristensen, J, Theodorsson, E, Holst, JJ & Efendic, S 2008, 'GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome', Neurogastroenterology and Motility Online, vol. 20, no. 6, pp. 649-59. https://doi.org/10.1111/j.1365-2982.2007.01079.x

APA

Hellström, P. M., Näslund, E., Edholm, T., Schmidt, P. T., Kristensen, J., Theodorsson, E., Holst, J. J., & Efendic, S. (2008). GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome. Neurogastroenterology and Motility Online, 20(6), 649-59. https://doi.org/10.1111/j.1365-2982.2007.01079.x

Vancouver

Hellström PM, Näslund E, Edholm T, Schmidt PT, Kristensen J, Theodorsson E et al. GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome. Neurogastroenterology and Motility Online. 2008 Jun;20(6):649-59. https://doi.org/10.1111/j.1365-2982.2007.01079.x

Author

Hellström, P M ; Näslund, E ; Edholm, T ; Schmidt, P T ; Kristensen, J ; Theodorsson, E ; Holst, Jens Juul ; Efendic, S. / GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome. In: Neurogastroenterology and Motility Online. 2008 ; Vol. 20, No. 6. pp. 649-59.

Bibtex

@article{e139e45f1b59435fac727757ec945213,
title = "GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome",
abstract = "Glucagon-like peptide-1 (GLP-1) is released after food intake to act as an incretin. GLP-1 also inhibits gastric emptying and increases satiety. In rats, GLP-1 inhibits small bowel motility. Our aim was to study the effects of GLP-1 on gastrointestinal motility in healthy subjects and patients with irritable bowel syndrome (IBS). Antro-duodeno-jejunal manometry was carried out during a 4-h control period with saline, followed by a 4-h period with intravenous GLP-1 (healthy: 0.7 and 1.2 pmol kg(-1) min(-1) (n = 16); IBS, 1.2 and 2.5 pmol kg(-1) min(-1) (n = 14). Plasma was analysed for GLP-1 and gut hormones, and gut tissue expression of GLP-1 receptor was studied. In healthy subjects, GLP-1 0.7 pmol kg(-1) min(-1) reduced the migrating motor complexes (MMCs) from a median of 2 (range 2-3) to 0.5 (0-2), and motility index from 4.9 +/- 0.1 to 4.3 +/- 0.3 ln Sigma(mmHg*s min(-1)) in jejunum, while GLP-1 1.2 pmol kg(-1) min(-1) diminished MMCs from 2 (2-3) to 1.5 (1-2.5), and motility index from 5.2 +/- 0.2 to 4.4 +/- 0.2. In IBS patients, GLP-1 1.2 pmol kg(-1) min(-1) reduced the MMCs from 2.5 (2-3.5) to 1 (0-1.5) without affecting motility index. At 2.5 pmol kg(-1) min(-1) GLP-1 decreased MMCs from 2 (1.5-3) to 1 (0.5-1.5), and motility index from 5.2 +/- 0.2 to 4.0 +/- 0.5. Motility responses to GLP-1 were similar in antrum and duodenum. Presence of the GLP-1 receptor in the gut was verified by reverse transcriptase PCR. In conclusion, the gut peptide GLP-1 decreases motility in the antro-duodeno-jejunal region and inhibits the MMC in healthy subjects and IBS patients.",
keywords = "Adolescent, Adult, Duodenum, Female, Gastrointestinal Motility, Glucagon-Like Peptide 1, Humans, Irritable Bowel Syndrome, Jejunum, Male, Middle Aged, Myoelectric Complex, Migrating, Pyloric Antrum",
author = "Hellstr{\"o}m, {P M} and E N{\"a}slund and T Edholm and Schmidt, {P T} and J Kristensen and E Theodorsson and Holst, {Jens Juul} and S Efendic",
year = "2008",
month = jun,
doi = "10.1111/j.1365-2982.2007.01079.x",
language = "English",
volume = "20",
pages = "649--59",
journal = "Neurogastroenterology and Motility Online",
issn = "1365-2982",
publisher = "Wiley-Blackwell",
number = "6",

}

RIS

TY - JOUR

T1 - GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome

AU - Hellström, P M

AU - Näslund, E

AU - Edholm, T

AU - Schmidt, P T

AU - Kristensen, J

AU - Theodorsson, E

AU - Holst, Jens Juul

AU - Efendic, S

PY - 2008/6

Y1 - 2008/6

N2 - Glucagon-like peptide-1 (GLP-1) is released after food intake to act as an incretin. GLP-1 also inhibits gastric emptying and increases satiety. In rats, GLP-1 inhibits small bowel motility. Our aim was to study the effects of GLP-1 on gastrointestinal motility in healthy subjects and patients with irritable bowel syndrome (IBS). Antro-duodeno-jejunal manometry was carried out during a 4-h control period with saline, followed by a 4-h period with intravenous GLP-1 (healthy: 0.7 and 1.2 pmol kg(-1) min(-1) (n = 16); IBS, 1.2 and 2.5 pmol kg(-1) min(-1) (n = 14). Plasma was analysed for GLP-1 and gut hormones, and gut tissue expression of GLP-1 receptor was studied. In healthy subjects, GLP-1 0.7 pmol kg(-1) min(-1) reduced the migrating motor complexes (MMCs) from a median of 2 (range 2-3) to 0.5 (0-2), and motility index from 4.9 +/- 0.1 to 4.3 +/- 0.3 ln Sigma(mmHg*s min(-1)) in jejunum, while GLP-1 1.2 pmol kg(-1) min(-1) diminished MMCs from 2 (2-3) to 1.5 (1-2.5), and motility index from 5.2 +/- 0.2 to 4.4 +/- 0.2. In IBS patients, GLP-1 1.2 pmol kg(-1) min(-1) reduced the MMCs from 2.5 (2-3.5) to 1 (0-1.5) without affecting motility index. At 2.5 pmol kg(-1) min(-1) GLP-1 decreased MMCs from 2 (1.5-3) to 1 (0.5-1.5), and motility index from 5.2 +/- 0.2 to 4.0 +/- 0.5. Motility responses to GLP-1 were similar in antrum and duodenum. Presence of the GLP-1 receptor in the gut was verified by reverse transcriptase PCR. In conclusion, the gut peptide GLP-1 decreases motility in the antro-duodeno-jejunal region and inhibits the MMC in healthy subjects and IBS patients.

AB - Glucagon-like peptide-1 (GLP-1) is released after food intake to act as an incretin. GLP-1 also inhibits gastric emptying and increases satiety. In rats, GLP-1 inhibits small bowel motility. Our aim was to study the effects of GLP-1 on gastrointestinal motility in healthy subjects and patients with irritable bowel syndrome (IBS). Antro-duodeno-jejunal manometry was carried out during a 4-h control period with saline, followed by a 4-h period with intravenous GLP-1 (healthy: 0.7 and 1.2 pmol kg(-1) min(-1) (n = 16); IBS, 1.2 and 2.5 pmol kg(-1) min(-1) (n = 14). Plasma was analysed for GLP-1 and gut hormones, and gut tissue expression of GLP-1 receptor was studied. In healthy subjects, GLP-1 0.7 pmol kg(-1) min(-1) reduced the migrating motor complexes (MMCs) from a median of 2 (range 2-3) to 0.5 (0-2), and motility index from 4.9 +/- 0.1 to 4.3 +/- 0.3 ln Sigma(mmHg*s min(-1)) in jejunum, while GLP-1 1.2 pmol kg(-1) min(-1) diminished MMCs from 2 (2-3) to 1.5 (1-2.5), and motility index from 5.2 +/- 0.2 to 4.4 +/- 0.2. In IBS patients, GLP-1 1.2 pmol kg(-1) min(-1) reduced the MMCs from 2.5 (2-3.5) to 1 (0-1.5) without affecting motility index. At 2.5 pmol kg(-1) min(-1) GLP-1 decreased MMCs from 2 (1.5-3) to 1 (0.5-1.5), and motility index from 5.2 +/- 0.2 to 4.0 +/- 0.5. Motility responses to GLP-1 were similar in antrum and duodenum. Presence of the GLP-1 receptor in the gut was verified by reverse transcriptase PCR. In conclusion, the gut peptide GLP-1 decreases motility in the antro-duodeno-jejunal region and inhibits the MMC in healthy subjects and IBS patients.

KW - Adolescent

KW - Adult

KW - Duodenum

KW - Female

KW - Gastrointestinal Motility

KW - Glucagon-Like Peptide 1

KW - Humans

KW - Irritable Bowel Syndrome

KW - Jejunum

KW - Male

KW - Middle Aged

KW - Myoelectric Complex, Migrating

KW - Pyloric Antrum

U2 - 10.1111/j.1365-2982.2007.01079.x

DO - 10.1111/j.1365-2982.2007.01079.x

M3 - Journal article

C2 - 18298441

VL - 20

SP - 649

EP - 659

JO - Neurogastroenterology and Motility Online

JF - Neurogastroenterology and Motility Online

SN - 1365-2982

IS - 6

ER -

ID: 132049307